HEC585 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	3

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05383131 (ClinicalTrials.gov)	June 23, 2021	12/5/2022	To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers	A Single Center, Open Label Study to Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers	Idiopathic Pulmonary Fibrosis	Drug: HEC585;Drug: Pirfenidone;Drug: Nintedanib	Sunshine Lake Pharma Co., Ltd.	NULL	Completed	18 Years	45 Years	All	33	Phase 1	China
2	NCT04512170 (ClinicalTrials.gov)	July 13, 2020	7/8/2020	Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects	A Randomized, Double-Blind, Placebo-Controlled Study of Ascending Single and Multiple Doses to Evaluate the Safety, Tolerability, Pharmacokinetics, and Randomized, Open-label,Crossover, Food Effect Study of HEC585 in Healthy Chinese Subjects	Idiopathic Pulmonary Fibrosis	Drug: HEC585;Drug: placebo	Sunshine Lake Pharma Co., Ltd.	NULL	Completed	18 Years	45 Years	All	72	Phase 1	China
3	NCT03092102 (ClinicalTrials.gov)	May 20, 2017	21/3/2017	The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects	A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects	Idiopathic Pulmonary Fibrosis	Drug: HEC585	Sunshine Lake Pharma Co., Ltd.	NULL	Completed	18 Years	60 Years	All	136	Phase 1	United States